The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

Vertex Pharmaceuticals got a fresh boost of confidence from H.C. Wainwright, which reaffirmed its Buy rating after the ADA ...

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

When Mayor Michelle Wu announced in April that an anonymous donor had given $1 million to the Boston Arts Academy in the ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.